Slideset: Hepatitis B Screening, Diagnosis, and Treatment Candidacy
Source: Understanding and Implementing the AASLD’s HBV Practice Guidelines and Other Recent Guidelines and Recommendations on the Diagnosis, Management, and Treatment of Hepatitis B

Slideset

Slideset: Hepatitis B Screening, Diagnosis, and Treatment Candidacy

In this downloadable slideset, Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, reviews the latest guideline recommendations on HBV screening, diagnosis, and treatment candidacy.
Format: Microsoft PowerPoint (.ppt)
File size: 5.78 MB
Date posted: 11/11/2010
  • My Approach to Identifying Treatment Candidates and Maintaining Patients on Long-term HBV Therapy

    Anna S. F. Lok MD - 6/19/2014    8 comments / Last Comment: 8/13/2014
    I find it helpful to discuss the impact of treatment on liver fibrosis/cirrhosis and hepatocellular carcinoma with patients, which motivates some to initiate and adhere to their long-term treatment.
  • The Age-Old Debate of Whether to Biopsy in HCV: My Answer for 2013

    Mark S. Sulkowski MD - 1/23/2013    17 comments / Last Comment: 11/2/2013
    With interferon-free, all-oral therapies on the near-term horizon, I am increasingly comfortable relying on patient history, physical exam, routine laboratory tests, and liver imaging as well as noninvasive serum markers to obtain a picture of liver health.
  • Treating HBV Patients With Cirrhosis: The Need for Vigilant HCC Screening

    Maria Buti MD - 5/14/2014    6 comments / Last Comment: 10/3/2014
    Antiviral therapy can dramatically improve liver histology, even in cirrhotic patients, but it remains critical to screen patients with suppressed viral load for hepatocellular carcinoma.
  • Coffee May Offer Real Benefits to the Liver

    Mark S. Sulkowski MD - 8/13/2013    8 comments / Last Comment: 5/31/2014
    The latest prescription for liver health in patients with hepatitis: coffee.
  • My Take on the Guidance From AASLD/IDSA for Treating Interferon-Ineligible Patients With Genotype 1 HCV Infection

    Paul Y. Kwo MD - 10/9/2014    
    Historically, evaluating patients for interferon eligibility was critical. Today, interferon-free regimens are evolving and soon they will be standard practice for even the most difficult-to-treat disease.